RecruitingPhase not listedNCT07677267
A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Sponsor: Novartis Pharmaceuticals
East Hanover, NJ